Loading…
State-owned Chinese animal-health company (Sinopharm) making veterinary vaccines and animal pharmaceuticals, plus livestock breeding.
State-owned Chinese animal-health company (Sinopharm) making veterinary vaccines and animal pharmaceuticals, plus livestock breeding.
Sells vaccines both to governments, which buy compulsory-immunisation vaccines through bidding rounds, and to farms and distributors in the open market, so state policy decides a large part of volumes. It sits under a state-owned group that spans animal health.
In one line: A Chinese Zoetis/Elanco for livestock.
Moat: narrow (regulatory licence, scale, distribution). State-backed veterinary vaccine licenses and a nationwide distribution network for disease-control programs.
Headquarters: Beijing, China · Employees: 3,996
Size China Animal Husbandry Industry (600195.SS) is a China Health Care company (Biotechnology) with a market value of $960M, the 2379th largest of 4,839 China companies the cockpit tracks. Shares closed at CN¥6.27 on 6 Nov 2026.
Performance Over six months the shares fell 16.6%, against -10.6% for the median peer and -16.4% for the China market (cap-weighted) — 8th lowest of 20 in its peer set.
Growth Revenue grew 1.1% over the last twelve months (peer median +0.6%); the operating margin is 1.8% (peer median -45.3%).
Valuation It trades at 35.8× forward earnings against a peer median of 27.3× (3rd most expensive of 7).
Price implies For today's price to make sense, revenue must grow about 7% a year for seven years (Req g). Recent delivered growth is +4%, so the hurdle is +2 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.
Capital Return on invested capital runs 2.9 points below its cost of capital (5.8% WACC).
Next results Next results expected around 9 Apr 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | CN¥6.34B | CN¥6.19B | CN¥5.98B | CN¥5.37B | CN¥5.88B |
| Revenue growth | — | +4% | +11% | -9% | — |
| Gross profit | CN¥1.34B | CN¥973M | CN¥827M | CN¥926M | CN¥1.16B |
| EBITDA | n/a | CN¥380M | CN¥357M | CN¥504M | CN¥634M |
| Net income | CN¥4.23M | CN¥171M | CN¥70.9M | CN¥403M | CN¥550M |
| Free cash flow | CN¥662M | CN¥962M | -CN¥16.0M | -CN¥246M | -CN¥607M |
| Capital expenditure | CN¥217M | CN¥241M | CN¥459M | CN¥643M | CN¥464M |
| Total debt | CN¥2.51B | CN¥1.66B | CN¥1.34B | CN¥1.46B | CN¥451M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g |
|---|---|---|---|---|---|---|
| China Animal Husbandry Industry 600195.SS | $960M | -17% | +1% | 2% | 35.8× | 6.6% |
| Zoetis ZTS | $32.8B | -4% | +1% | 38% | 12.8× | -4.3% |
| Elanco Animal Health ELAN | $12.9B | +9% | +12% | 7% | 21.8× | 34.8% |
| Pulike Biological Engineering 603566.SS | $475M | -22% | -9% | 5% | 21.0× | 5.7% |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 600195.SS | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -5.6% | -3.2% | 8th lowest of 21 |
| 6-month return | -16.6% | -10.6% | 8th lowest of 20 |
| Distance from 52-week high | -30.6% | -41.2% | 3rd highest of 21 |
| Revenue growth (TTM) | +1.1% | +0.6% | 9th highest of 18 |
| Operating margin | 1.8% | -45.3% | 5th highest of 19 |
| Forward P/E | 35.8× | 27.3× | 3rd most expensive of 7 |
| Growth the price implies (Req g, 7 yrs) | 6.6% | 10.0% | 3rd least demanding of 7 |
| Growth delivered (Del g) | +4.4% | -1.7% | 2nd highest of 7 |
| Hurdle (Req g minus delivered) | +2.2 pp | +15.5 pp | 2nd least demanding of 7 |
| ROIC minus cost of capital | -2.9 pp | -11.8 pp | 5th highest of 13 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| China Animal Husbandry Industry 600195.SS | China | $960M | -17% | +1% | 2% | 35.8× | 6.6% | +4.4% |
| Jade Biosciences JBIO | United States | $958M | -42% | n/a | n/a | n/a | n/a | n/a |
| Alto Neuroscience ANRO | United States | $987M | +4% | n/a | n/a | n/a | n/a | n/a |
| Nanjing Leads Biolabs 9887.HK | Hong Kong | $927M | -54% | n/a | -108% | n/a | n/a | n/a |
| Chengdu Kanghua Biological Products Co. Td Class 1 300841.SZ | China | $995M | -11% | 0% | 22% | 23.6× | 11.1% | +2.3% |
| Odyssey Therapeutics ODTX | United States | $924M | n/a | -33% | -5,415% | n/a | n/a | n/a |
| Changchun BCHT Biotechnology 688276.SS | China | $1.00B | -11% | +2% | -29% | n/a | n/a | n/a |
| Inventiva IVA.PA | France | $912M | -29% | -100% | -307,063% | n/a | n/a | n/a |
| Innovita Biological Technology 688253.SS | China | $1.02B | -4% | -28% | 11% | 103.0× | 42.9% | -16.6% |
| Verastem VSTM | United States | $1.02B | +72% | +3,996% | -183% | n/a | n/a | n/a |
| Monte Rosa Therapeutics GLUE | United States | $902M | -45% | -84% | -633% | n/a | n/a | n/a |
| Oxford BioMedica OXB.L | United Kingdom | $892M | -14% | +16% | -18% | n/a | n/a | n/a |
| GNI 2160.T | Japan | $866M | -29% | +10% | -24% | 135.6× | n/a | n/a |
| MeiraGTx MGTX | United States | $864M | -8% | +948% | 46% | n/a | -9.9% | +39.2% |
| Syndax Pharmaceuticals SNDX | United States | $859M | -56% | +160% | -62% | n/a | n/a | n/a |
| Janux Therapeutics JANX | United States | $1.08B | +24% | +5,367% | -598% | n/a | n/a | n/a |
| Peptidream 4587.T | Japan | $856M | -10% | +1% | -25% | 20.0× | n/a | n/a |
| Prime Medicine PRME | United States | $843M | +45% | -18% | -4,825% | n/a | n/a | n/a |
| Daan Gene 002030.SZ | China | $1.11B | -9% | +1% | -81% | n/a | 5.7% | -32.3% |
| Wuhan Keqian Biology 688526.SS | China | $814M | -19% | -22% | 20% | 16.6× | 8.8% | +2.4% |
| Guangzhou Wondfo Biotech 300482.SZ | China | $1.14B | -10% | -24% | -2% | 31.0× | 16.4% | -5.8% |